Volume 5.07 | Feb 25

Pulmonary Cell News 5.07 February 25, 2016
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PULCN on Twitter
The Oxygen Environment at Birth Specifies the Population of Alveolar Epithelial Stem Cells in the Adult Lung
BrdU labeling, genetic lineage tracing, and targeted expression of the anti-oxidant extracellular superoxide dismutase in alveolar epithelial type II cells (AEC2s) were used to show how the oxygen environment at birth influences postnatal expansion of AEC2s and AEC1s in mice. [Stem Cells] Abstract
Air-Liquid Interface Culture for Respiratory Research: Watch Q&A Video
PUBLICATIONS (Ranked by impact factor of the journal)
Long-Term Exposure of A549 Cells to Titanium Dioxide Nanoparticles Induces DNA Damage and Sensitizes Cells towards Genotoxic Agents
Scientists demonstrated that long-term exposure to titanium dioxide nanoparticles does not affect cell viability but causes DNA damage, particularly oxidative damage to DNA and increased 53BP1 foci counts, correlated with increased intracellular accumulation of nanoparticles. [Nanotoxicology] Abstract

Specific Regulation of PRMT1 Expression by PIAS1 and RKIP in BEAS-2B Epithelia Cells and HFL-1 Fibroblasts in Lung Inflammation
The authors investigated the cell type specific regulatory mechanism of protein arginine methyltransferase 1 (PRMT1). Epithelial cells and fibroblasts were stimulated with IL-4 or IL-1β. [Sci Rep] Full Article

Linocin and OmpW Are Involved in Attachment of the Cystic Fibrosis Associated Pathogen Burkholderia cepacia Complex to Lung Epithelial Cells and Protect Mice against Infection
Investigators developed a new proteomics approach to identify bacterial proteins that are involved in attachment of Burkholderia cepacia complex to lung epithelial cells. [Infect Immun] Abstract

Effects of Lipopolysaccharide, Multiwalled Carbon Nanotubes, and the Combination on Lung Alveolar Epithelial Cells
Scientists investigated the effects of lipopolysaccharide (LPS), multiwalled carbon nanotubes (MWCNT), and the combination of LPS and MWCNT on the expression of matrix metalloproteinase-9 and metalloproteinase-12, collagen 3A1, and transforming growth factor beta in alveolar epithelial A549 cells. [Environ Toxicol] Abstract


PARP1 Enhances Lung Adenocarcinoma Metastasis by Novel Mechanisms Independent of DNA Repair
The authors find that poly (ADP-ribose) polymerase 1 (PARP1) expression is associated with overall and distant metastasis-free survival in lung adenocarcinoma patients. Consistent with this, genetic knockdown and pharmacological inhibition of PARP1 significantly attenuated the metastatic potential of lung adenocarcinoma cells. [Oncogene] Abstract

Inhibitory Effect of Traditional Oriental Medicine-Derived Monoamine Oxidase B Inhibitor on Radioresistance of Non-Small Cell Lung Cancer
Danshensu, which is a selected component of traditional oriental medicine compound, was found to reduce the radioresistance of non-small cell lung cancer by inhibiting the nuclear factor-κB pathway. [Sci Rep] Full Article

Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in Progression of Lung Adenocarcinoma
A series of assays conducted in DEP domain-containing mTOR-interacting protein (DEPTOR) knockout or ectopic expression in A549 cells confirmed that DEPTOR inhibited proliferation, migration, and invasion as well as the in vivo tumor growth of lung adenocarcinoma. [Mol Cancer Res] Abstract

The Repair Capacity of Lung Cancer Cell Lines A549 and H1299 Depends on HMGB1 Expression Level and the p53 Status
Researchers demonstrated that overexpression of high mobility group box 1 (HMGB1) protein inhibited cis-platinated DNA repair in vivo and the effect strongly depended on its C-terminus. They registered increased levels of DNA repair after HMGB1 silencing only in p53 defective H1299 lung cancer cells. [J Biochem] Abstract

Learn More: Standardized Tools for Cancer Research
Tubulin Inhibitors in Non-Small Cell Lung Cancer: Looking Back and Forward
In this review, microtubule targeting agents (MTA) are classified according to their mechanism of action, with a focus on the most common mechanisms of resistance. Moreover, an overview of the most remarkable clinical data regarding MTA in adjuvant, neoadjuvant and advanced setting is provided. [Expert Opin Pharmacother] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children
Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. [Cancer MoonShot 2020] Press Release

First Patients Enrolled and Dosed in the Pivotal Trial of Phase III of the Immunotherapy Tedopi® for Advanced Non-Small Cell Lung Cancer
OSE Pharma SA, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase III study, announced enrolment and treatment of the first patients in its Atalante 1 Phase III trial. [OSE Pharma SA] Press Release

Strategia Therapeutics Initiates a Phase I Clinical Trial of the Anti-Cancer Agent “FF-10502″ For FUJIFILM in Patients with Advanced Cancers
Strategia Therapeutics has initiated a Phase I clinical trial of FUJIFILM’s anti-cancer agent FF-10502 in the United States in patients with advanced solid tumor cancers and lymphoma. [Strategia Therapeutics, Inc.] Press Release

Cutting Edge Medical Research Ideas Receive £23.2 Million Boost
The Medical Research Council is accelerating innovative medical research with £23.2 million in new funding to take ground-breaking ideas from UK universities into industry and out to patients. [Medical Research Council] Press Release

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells.
Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd Immunotherapy of Cancer Conference (ITOC)
March 21-23, 2016
Munich, Germany

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW Postdoctoral Fellow – Lung Cancer (The University of Texas MD Anderson Cancer Center)

Associate or Full Professor – Cardiothoracic Surgery (University of California San Diego)

Scientist – Lung Stem Cells (United Therapeutics Corporation)

Postdoctoral Research Fellow – Lung Cancer (Cornell University)

PhD Student Position – Asthma Research (Karolinska Institutet)

Postdoctoral Fellow – Lung Cancer Research (German Cancer Research Center)

Project Scientist – Pulmonary Fibrosis (Cedars Sinai Medical Center)

Postdoctoral Fellow – Bioinformatics RNA Biology & Cancer (German Cancer Research Center)

Postdoctoral Fellow/Research Associate – Cancer Therapy (Memorial Sloan Kettering Cancer Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Researcher – Immunology (Research Centre for Respiratory Diseases)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us